专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3292869A1 KAL1 PROTEIN CONTROLLING CELL CYCLE OF HEMATOPOIETIC STEM CELL, AND USE THEREOF 有权
标题翻译： KAL1蛋白控制造血干细胞的细胞周期及其应用
公开(公告)号：EP3292869A1
公开(公告)日：2018-03-14
申请号：EP16789620.8
申请日：2016-05-04
申请人： Seoul National University R & DB Foundation
发明人： KIM, Hyo-Soo , HUR, Jin , CHOI, Jae Il
IPC分类号： A61K38/17 , C12N5/0789 , C07K14/705 , A61K35/28
CPC分类号： A61K35/28 , A61K38/17 , A61K2035/124 , A61P35/00 , C07K14/705 , C12N5/0081 , C12N5/0634 , C12N2502/1157 , C12N2502/1171
摘要： The present invention relates to a KAl1 protein controlling the cell cycle of a hematopoietic stem cell and a use thereof, and more specifically, a composition comprising a KAl1(CD82) polypeptide or a gene encoding the same for controlling the cell cycle of a hematopoietic stem cell, or a pharmaceutical composition for preventing or treating blood tumors. In the present invention, KAI1(CD82) is expressed only in a hematopoietic stem cell (LT-HSC) which is the uppermost stem cell in the hierarchy of the hematopoietic stem cell, can obtain an LT-HSC with high purity using the KAl1, and thus can inhibit various side effects of hematopoietic stem cell transplantation by transplanting only an LT-HSC with high purity. In addition, KAl1 importantly acts on the quiescence of an LT-HSC, and has resistance against cell damage due to various stresses (5-FU, irradiation, etc.) by maintaining the quiescence of the LT-HSC. Thus, it is expected that the cell can be used for making a cell bank and can be used as a blood tumor cell therapy product through cell transplantation.
摘要翻译：本发明涉及控制造血干细胞的细胞周期的KAl1蛋白及其用途，更具体地涉及包含KAl1（CD82）多肽或编码其的用于控制造血干细胞的细胞周期的基因的组合物细胞或用于预防或治疗血液肿瘤的药物组合物。在本发明中，KAI1（CD82）仅在造血干细胞层次中最上层的干细胞 - 造血干细胞（LT-HSC）中表达，可以使用KAl1获得高纯度的LT-HSC，因此通过仅移植高纯度的LT-HSC可以抑制造血干细胞移植的各种副作用。此外，KAl1通过维持LT-HSC的静止而重要地作用于LT-HSC的静止，并且具有抗各种应激（5-FU，辐射等）引起的细胞损伤。因此，预计细胞可用于制造细胞库，并可通过细胞移植用作血液肿瘤细胞治疗产品。

IPRDB

热门服务

关于我们

友情链接

联系方式